[go: up one dir, main page]

MX2016007370A - Agente terapeutico y/o preventivo que comprende un derivado de 1-indansulfamida para el dolor. - Google Patents

Agente terapeutico y/o preventivo que comprende un derivado de 1-indansulfamida para el dolor.

Info

Publication number
MX2016007370A
MX2016007370A MX2016007370A MX2016007370A MX2016007370A MX 2016007370 A MX2016007370 A MX 2016007370A MX 2016007370 A MX2016007370 A MX 2016007370A MX 2016007370 A MX2016007370 A MX 2016007370A MX 2016007370 A MX2016007370 A MX 2016007370A
Authority
MX
Mexico
Prior art keywords
indansulfamide
pain
therapeutic
derivative
preventive agent
Prior art date
Application number
MX2016007370A
Other languages
English (en)
Other versions
MX370898B (es
Inventor
Kazuta Yuji
Higashiyama Hiroyuki
Hashimoto Keisuke
Original Assignee
Eisai R&D Man Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eisai R&D Man Co Ltd filed Critical Eisai R&D Man Co Ltd
Publication of MX2016007370A publication Critical patent/MX2016007370A/es
Publication of MX370898B publication Critical patent/MX370898B/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • A61K31/165Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • A61K31/18Sulfonamides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021Intradermal administration, e.g. through microneedle arrays, needleless injectors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Rheumatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)

Abstract

Un medicamento que comprende un compuesto de 1-indansulfamidas tal como N-[(1S)-2,2,5,7-tetrafluoro-2,3-dihidro-1H-inden-1-il] sulfamida o N-[(1S)-2,2-difluoro-7-metil-2,3-dihidro-1H-indeno-1-i l]sulfamida, o una de sus sales farmacéuticamente aceptables, tiene efectos analgésicos en la prueba de la placa caliente en ratones y el modelo de la lesión nerviosa por constricción en ratas y, por lo tanto, resulta prometedor como agente terapéutico para el dolor agudo y crónico.
MX2016007370A 2013-12-19 2014-12-17 Agente terapéutico y/o preventivo que comprende un derivado de 1-indansulfamida para el dolor. MX370898B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2013262743 2013-12-19
PCT/JP2014/083374 WO2015093515A1 (ja) 2013-12-19 2014-12-17 1-インダンスルファミド誘導体を含む疼痛の治療および/または予防剤

Publications (2)

Publication Number Publication Date
MX2016007370A true MX2016007370A (es) 2016-10-03
MX370898B MX370898B (es) 2020-01-09

Family

ID=53402860

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016007370A MX370898B (es) 2013-12-19 2014-12-17 Agente terapéutico y/o preventivo que comprende un derivado de 1-indansulfamida para el dolor.

Country Status (14)

Country Link
US (1) US9610262B2 (es)
EP (1) EP3085369B1 (es)
JP (1) JP6518595B2 (es)
KR (1) KR102250214B1 (es)
CN (1) CN105792821B (es)
AU (1) AU2014367781B2 (es)
BR (1) BR112016012833B1 (es)
CA (1) CA2932529C (es)
ES (1) ES2673876T3 (es)
IL (1) IL246036B (es)
MX (1) MX370898B (es)
RU (1) RU2678571C1 (es)
SG (1) SG11201604484UA (es)
WO (1) WO2015093515A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2020128731A (ru) * 2018-03-20 2022-04-20 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. Средство для лечения эпилепсии
JPWO2023210617A1 (es) 2022-04-27 2023-11-02
KR102815521B1 (ko) 2022-11-11 2025-06-04 덕산에테르씨티 주식회사 내화성능 및 강도가 보강된 압력용기
KR102815520B1 (ko) 2022-11-11 2025-06-04 덕산에테르씨티 주식회사 내화성능 및 강도가 보강된 압력용기
KR102803991B1 (ko) 2022-11-11 2025-05-13 덕산에테르씨티 주식회사 내화성능 및 강도가 보강된 압력용기
KR20250063589A (ko) 2023-11-01 2025-05-08 덕산에테르씨티 주식회사 압력 용기의 숄더부 보호용 커버

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8716231B2 (en) 2005-12-19 2014-05-06 Janssen Pharmaceutica Nv Use of benzo-fused heterocycle sulfamide derivatives for the treatment of pain
US20070191452A1 (en) * 2006-02-15 2007-08-16 Smith-Swintosky Virginia L Use of benzo-heteroaryl sulfamide derivatives for the treatment of pain
CL2007002994A1 (es) * 2006-10-19 2008-02-08 Wyeth Corp Compuestos derivados heterociclicos que contienen sulfamoilo, inhibidores de hsp90; composicion farmaceutica; y uso para el tratamiento del cancer, tal como cancer de mama, de colon y prostata, entre otros.
TWI433674B (zh) 2006-12-28 2014-04-11 Infinity Discovery Inc 環杷明(cyclopamine)類似物類
JP2012523393A (ja) * 2009-04-09 2012-10-04 エム・エス・ディー・オス・ベー・フェー インダン誘導体
TW201217312A (en) 2010-09-22 2012-05-01 Gruenenthal Gmbh Substituted benzamide compounds
RU2508295C2 (ru) * 2012-03-22 2014-02-27 Общество с ограниченной ответственностью "Биофармокс" Синтетические пептиды с ненаркотическим типом анальгетического действия
EP2865663B1 (en) * 2012-06-21 2017-04-05 Eisai R&D Management Co., Ltd. Novel indanesulfamide derivative

Also Published As

Publication number Publication date
IL246036A0 (en) 2016-07-31
EP3085369B1 (en) 2018-04-04
CN105792821A (zh) 2016-07-20
CA2932529C (en) 2022-03-22
US20160303058A1 (en) 2016-10-20
WO2015093515A1 (ja) 2015-06-25
MX370898B (es) 2020-01-09
KR102250214B1 (ko) 2021-05-07
RU2016122189A (ru) 2018-01-24
AU2014367781A1 (en) 2016-06-23
US9610262B2 (en) 2017-04-04
IL246036B (en) 2018-11-29
EP3085369A1 (en) 2016-10-26
JP6518595B2 (ja) 2019-05-22
CN105792821B (zh) 2018-05-04
CA2932529A1 (en) 2015-06-25
RU2678571C1 (ru) 2019-01-30
AU2014367781B2 (en) 2019-07-04
EP3085369A4 (en) 2017-05-10
BR112016012833A2 (es) 2017-08-08
SG11201604484UA (en) 2016-07-28
JPWO2015093515A1 (ja) 2017-03-23
BR112016012833B1 (pt) 2022-11-16
KR20160106053A (ko) 2016-09-09
ES2673876T3 (es) 2018-06-26

Similar Documents

Publication Publication Date Title
CA2909335C (en) Fenfluramine for use in the treatment of dravet syndrome
MY179696A (en) Compositions and methods comprising bupropion or related compounds and dextromethorphan
MX365939B (es) Moduladores del transporte nuclear y usos de los mismos.
MX378263B (es) Terapia de combinación para el tratamiento del cáncer.
MY189466A (en) Methods of modulating drug plasma levels using erythrohydroxybupropion
WO2015077503A8 (en) Autotaxin inhibitor compounds
WO2015031564A3 (en) Substituted-1h-benzo[d]imidazole compounds as lysine-specific demethylase 1 (lsd1 ) inhibitors
MX2015016344A (es) Derivados de imidazo-pirrolidinona y su uso en el tratamiento de enfermedades.
MX2016007370A (es) Agente terapeutico y/o preventivo que comprende un derivado de 1-indansulfamida para el dolor.
WO2015056094A3 (en) Pharmaceutical composition comprising a trpa1 antagonist and an analgesic agent
WO2013048558A3 (en) Methods of therapeutic monitoring of nitrogen scavenging drugs
EP3308785A3 (en) Use of flecainide as an anti-connexin agent and method for potentiating the effects of a psychotropic drug
EP3513789A3 (en) Prophylactic and therapeutic agents for fgfr3 diseases
EP4424323A3 (en) Anti-folr1 immunoconjugate dosing regimens
WO2014153009A3 (en) Thiosaccharide mucolytic agents
WO2014106825A3 (en) Methods and devices for identifying improper medical reporting
MX2019008817A (es) Formulacion de liberacion prolongada para reducir la frecuencia de miccion y metodo de uso de la misma.
WO2014153385A3 (en) Methods of treating metabolic disorders
WO2015079010A3 (en) Pharmaceutical composition comprising lacosamide and levetiracetam
TN2019000032A1 (en) Pharmaceutical compositions and uses directed to lysosomal storage disorders
HK1223825A1 (zh) 包含阿曲生坦的稳定化药物剂型
MX368734B (es) (s)-pirlindol o sus sales farmaceuticamente aceptables para uso en medicina.
MX2014014814A (es) Composicion farmaceutica para el tratamiento de inflamacion y dolor.
MX368640B (es) Composición farmacéutica para tratar inflamación y dolor.
MX2014014817A (es) Compuestos para el tratamiento de inflamacion y dolor.

Legal Events

Date Code Title Description
FG Grant or registration